Trial Profile
A Phase Ib/IIa Study of Rucaparib (PARP Inhibitor) Combined With Nivolumab in Metastatic Castrate - Resistant Prostate Cancer and Advanced/Recurrent Endometrial Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Rucaparib (Primary)
- Indications Endometrial cancer; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 26 Jan 2021 Status changed from active, no longer recruiting to discontinued(The study was terminated due to lack of efficacy).
- 20 May 2020 Planned End Date changed from 1 Nov 2022 to 1 Dec 2021.
- 20 May 2020 Status changed from recruiting to active, no longer recruiting.